Filing Flows › Rapport Therapeutics (RAPP) › Recalls, complaints & regulation

Rapport Therapeutics (RAPP): clinical trials

Rapport Therapeutics (RAPP) beyond its filings: 3 active clinical trials.

Rapport Therapeutics' latest quarter

Rapport Therapeutics, Q1 2026: revenue $20.0M, operating margin -121.1%, net loss $19.9M, operating cash flow −$13.1M. The chart follows the revenue to costs, profit and cash.

Questions

How many clinical trials does Rapport Therapeutics have?

3 active studies on ClinicalTrials.gov, 2 in phase 3.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.